Biocon Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
24
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 14 to 28, 2027 · next Jan 14
- 3 fees due Feb 11 to 20, 2027 · next Feb 11
- 1 fee due Apr 29, 2027The maintenance fee for Crystalline Forms of Posaconazole Intermediate and Process for the Preparation of Amorphous Posaconazole (US 10,457,668) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due Jun 22, 2027The maintenance fee for Monoclonal Antibody and a Method Thereof (US 9,217,037) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 2 fees due Jul 7 to 26, 2027 · next Jul 7
- 1 fee due Aug 9, 2027The maintenance fee for Fermentation medias and processes thereof (US 9,255,285) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 2 fees due Nov 14 to 17, 2027 · next Nov 14
Recent changes
- 1 term has ended since Aug 24, 2026
- Oct 1 US 7,635,675 Micro-particle fatty acid salt solid dosage formulations for therapeutic agents · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,329,958 | Combinatorial synthesis of PEG oligomer libraries In force · USPTO record | In force | USPTO record | |
| US 8,563,685 | Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof In force · USPTO record | In force | USPTO record | |
| US 8,058,391 | Process for the preparation of insulin conjugate IN-105 In force · USPTO record | In force | USPTO record | |
| US 7,872,095 | Insulin-oligomer conjugates, formulations and uses thereof In force · USPTO record | In force | USPTO record | |
| US 7,875,700 | Cation complexes of insulin compound conjugates, formulation and uses thereof In force · USPTO record | In force | USPTO record | |
| US 7,932,366 | Synthesis of azo bonded immunoregulatory compounds In force · USPTO record | In force | USPTO record | |
| US 9,101,596 | Cation complexes of insulin compound conjugates, formulations and uses thereof In force · USPTO record | In force | USPTO record | |
| US 8,802,816 | Method of obtaining a purified, biologically active heterologous protein In force · USPTO record | In force | USPTO record | |
| US 9,102,758 | Insulin-oligomer conjugates, formulations and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,670,285 | Monoclonal Antibody and a Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 65: 50 lapsed for an unpaid fee · 47 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 6 abandoned · 15 no status recorded
Showing 1 to 10 of 30, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/236,781 | Jun 12, 2025 | No status recorded | |
| 18/746,907 | Targeted/Immunomodulatory Fusion Proteins and Methods for Making Same | Jun 18, 2024 | Pending |
| 18/630,519 | Monoclonal Antibody and a Method Thereof | Apr 9, 2024 | Pending |
| 18/335,542 | Use of Itolizumab to Reduce Phosphorylation of CD6 | Jun 15, 2023 | Pending |
| 18/199,675 | Formulations of Antibody | May 19, 2023 | Pending |
| 18/689,550 | Preparation Method of Echinocandin Nucleus | Sep 7, 2022 | Pending |
| 18/682,254 | Purification of Liraglutide | Aug 9, 2022 | Pending |
| 18/283,281 | Process for Preparation of Cabozantinib | Mar 24, 2022 | Pending |
| 18/270,520 | Synthesis of Teduglutide | Jan 3, 2022 | Pending |
| 17/559,382 | Monoclonal Antibody and a Method of Use for the Treatment of Lupus | Dec 22, 2021 | Abandoned |
10 of 30 applications shown.
Pro members see all 30 published applications.